Curia Capabilities Update May 2026: Highly Potent Drug Development & Manufacturing

High potency APIs demand a level of manufacturing expertise that goes far beyond standard small-molecule production. This presentation equips innovators with the right questions to ask when selecting a CDMO partner, covering the full range of critical considerations from early development through commercial scale.

Topics include hazard assessment and occupational exposure banding, engineering controls and containment strategies, cleaning validation for low-solubility compounds, and the value of integrated R&D and analytical capabilities under one roof. Watch as Brian P. Haney, Ph.D., Senior Director of Technical Operations, addresses the importance of corporate-level commitment to HP API safety — not just equipment — and what third-party certification programs like SafeBridge Associates signal about a site's standards.

The presentation closes with an overview of Curia's global HP API network, with its Center of Excellence in Rensselaer, New York, and a dedicated steroids and hormones facility in Valladolid, Spain.